{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T12:00:21Z","timestamp":1781092821006,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,10]]},"DOI":"10.7759\/cureus.110588","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:05:02Z","timestamp":1781089502000},"source":"Crossref","is-referenced-by-count":0,"title":["A Unifying Model of Inflammatory Amplification: Insights From Colchicine Across Cardiometabolic and Infectious Disease"],"prefix":"10.7759","author":[{"given":"Amir B","family":"Rabbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab438","article-title":"The changing nature of atherosclerosis: what we thought we knew, what we think we know, and what we have to learn","volume":"42","author":"Libby P","year":"2021","unstructured":"Libby P. The changing nature of atherosclerosis: what we thought we knew, what we think we know, and what we have to learn. Eur Heart J. 2021, 42:4781-2. 10.1093\/eurheartj\/ehab438","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.052","article-title":"C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus","volume":"49","author":"Ridker PM","year":"2007","unstructured":"Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007, 49:2129-38. 10.1016\/j.jacc.2007.02.052","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman D","year":"2019","unstructured":"Furman D, Campisi J, Verdin E, et al.. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019, 25:1822-32. 10.1038\/s41591-019-0675-0","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3790","article-title":"A guiding map for inflammation","volume":"18","author":"Netea MG","year":"2017","unstructured":"Netea MG, Balkwill F, Chonchol M, et al.. A guiding map for inflammation. Nat Immunol. 2017, 18:826-31. 10.1038\/ni.3790","journal-title":"Nat Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil GS","year":"2017","unstructured":"Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017, 542:177-85. 10.1038\/nature21363","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson KV","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019, 19:477-89. 10.1038\/s41577-019-0165-0","journal-title":"Nat Rev Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1232629","article-title":"Reframing the link between metabolism and NLRP3 inflammasome: therapeutic opportunities","volume":"14","author":"Ortega MA","year":"2023","unstructured":"Ortega MA, De Leon-Oliva D, Garc\u00eda-Montero C, et al.. Reframing the link between metabolism and NLRP3 inflammasome: therapeutic opportunities. Front Immunol. 2023, 14:1232629. 10.3389\/fimmu.2023.1232629","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02368-9","article-title":"Immuno-metabolic diseases and therapeutics: molecular mechanisms via inflammasome signaling","volume":"23","author":"Han JH","year":"2025","unstructured":"Han JH. Immuno-metabolic diseases and therapeutics: molecular mechanisms via inflammasome signaling. Cell Commun Signal. 2025, 23:373. 10.1186\/s12964-025-02368-9","journal-title":"Cell Commun Signal"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine--update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung YY","year":"2015","unstructured":"Leung YY, Yao Hui LL, Kraus VB. Colchicine--update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015, 45:341-50. 10.1016\/j.semarthrit.2015.06.013","journal-title":"Semin Arthritis Rheum"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif JC","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, et al.. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019, 381:2497-505. 10.1056\/NEJMoa1912388","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf SM","year":"2020","unstructured":"Nidorf SM, Fiolet AT, Mosterd A, et al.. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020, 383:1838-47. 10.1056\/NEJMoa2021372","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov R","year":"2008","unstructured":"Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008, 454:428-35. 10.1038\/nature07201","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3123","article-title":"Control of adaptive immunity by the innate immune system","volume":"16","author":"Iwasaki A","year":"2015","unstructured":"Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015, 16:343-53. 10.1038\/ni.3123","journal-title":"Nat Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.714","article-title":"The interaction of innate immune and adaptive immune system","volume":"5","author":"Wang R","year":"2024","unstructured":"Wang R, Lan C, Benlagha K, et al.. The interaction of innate immune and adaptive immune system. MedComm (2020). 2024, 5:e714. 10.1002\/mco2.714","journal-title":"MedComm (2020)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi O","year":"2010","unstructured":"Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010, 140:805-20. 10.1016\/j.cell.2010.01.022","journal-title":"Cell"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: function, regulation and therapeutic potential","volume":"10","author":"Chen R","year":"2025","unstructured":"Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct Target Ther. 2025, 10:216. 10.1038\/s41392-025-02264-1","journal-title":"Signal Transduct Target Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea MG","year":"2016","unstructured":"Netea MG, Joosten LA, Latz E, et al.. Trained immunity: a program of innate immune memory in health and disease. Science. 2016, 352:aaf1098. 10.1126\/science.aaf1098","journal-title":"Science"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-083122-040624","article-title":"Bidirectional communication between the innate and adaptive immune systems","volume":"43","author":"Warrick KA","year":"2025","unstructured":"Warrick KA, Vallez CN, Meibers HE, Pasare C. Bidirectional communication between the innate and adaptive immune systems. Annu Rev Immunol. 2025, 43:489-514. 10.1146\/annurev-immunol-083122-040624","journal-title":"Annu Rev Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi S","year":"2020","unstructured":"Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol. 2020, 38:541-66. 10.1146\/annurev-immunol-042718-041717","journal-title":"Annu Rev Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI34431","article-title":"A calculated response: control of inflammation by the innate immune system","volume":"118","author":"Barton GM","year":"2008","unstructured":"Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest. 2008, 118:413-20. 10.1172\/JCI34431","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2024.04.006","article-title":"Metabolism-inflammasome crosstalk shapes innate and adaptive immunity","volume":"31","author":"Wu J","year":"2024","unstructured":"Wu J, Sun X, Jiang P. Metabolism-inflammasome crosstalk shapes innate and adaptive immunity. Cell Chem Biol. 2024, 31:884-903. 10.1016\/j.chembiol.2024.04.006","journal-title":"Cell Chem Biol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea MG","year":"2020","unstructured":"Netea MG, Dom\u00ednguez-Andr\u00e9s J, Barreiro LB, et al.. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020, 20:375-88. 10.1038\/s41577-020-0285-6","journal-title":"Nat Rev Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker PM","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al.. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017, 377:1119-31. 10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley N","year":"2019","unstructured":"Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019, 20:10.3390\/ijms20133328","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00211","article-title":"NLRP3 inflammasome-a key player in antiviral responses","volume":"11","author":"Zhao C","year":"2020","unstructured":"Zhao C, Zhao W. NLRP3 inflammasome-a key player in antiviral responses. Front Immunol. 2020, 11:211. 10.3389\/fimmu.2020.00211","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind FG","year":"2009","unstructured":"Bauernfeind FG, Horvath G, Stutz A, et al.. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009, 183:787-91. 10.4049\/jimmunol.0901363","journal-title":"J Immunol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe A","year":"2018","unstructured":"Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res. 2018, 122:1722-40. 10.1161\/CIRCRESAHA.118.311362","journal-title":"Circ Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell P","year":"2010","unstructured":"Duewell P, Kono H, Rayner KJ, et al.. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010, 464:1357-61. 10.1038\/nature08938","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.920464","article-title":"Pyroptosis and respiratory diseases: a review of current knowledge","volume":"13","author":"Sun J","year":"2022","unstructured":"Sun J, Li Y. Pyroptosis and respiratory diseases: a review of current knowledge. Front Immunol. 2022, 13:920464. 10.3389\/fimmu.2022.920464","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.12.013","article-title":"Western diet triggers NLRP3-dependent innate immune reprogramming","volume":"172","author":"Christ A","year":"2018","unstructured":"Christ A, G\u00fcnther P, Lauterbach MA, et al.. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell. 2018, 172:162-175.e14. 10.1016\/j.cell.2017.12.013","journal-title":"Cell"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello CA","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011, 117:3720-32. 10.1182\/blood-2010-07-273417","journal-title":"Blood"},{"key":"ref32","article-title":"Something old, something new--colchicine in the 21st century","volume":"10","author":"Cronstein BN","year":"2009","unstructured":"Cronstein BN. Something old, something new--colchicine in the 21st century. Curr Opin Investig Drugs. 2009, 10:1141-1142.","journal-title":"Curr Opin Investig Drugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.12.010","article-title":"Colchicine: old and new","volume":"128","author":"Slobodnick A","year":"2015","unstructured":"Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med. 2015, 128:461-70. 10.1016\/j.amjmed.2014.12.010","journal-title":"Am J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout","volume":"39","author":"Crittenden DB","year":"2012","unstructured":"Crittenden DB, Lehmann RA, Schneck L, et al.. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012, 39:1458-64. 10.3899\/jrheum.111533","journal-title":"J Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa T","year":"2013","unstructured":"Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, Akira S. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013, 14:454-60. 10.1038\/ni.2550","journal-title":"Nat Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-11116-8","article-title":"The NLRP3 inflammasome: a pivotal orchestrator of multisystem diseases-from molecular mechanisms to therapeutic innovation","volume":"52","author":"Xiao SY","year":"2025","unstructured":"Xiao SY, Lv YH, Ji YM, et al.. The NLRP3 inflammasome: a pivotal orchestrator of multisystem diseases-from molecular mechanisms to therapeutic innovation. Mol Biol Rep. 2025, 52:1026. 10.1007\/s11033-025-11116-8","journal-title":"Mol Biol Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab221","article-title":"Colchicine and the heart","volume":"42","author":"Imazio M","year":"2021","unstructured":"Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021, 42:2745-60. 10.1093\/eurheartj\/ehab221","journal-title":"Eur Heart J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2020.03.002","article-title":"The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): rationale and study design","volume":"61","author":"Deftereos SG","year":"2020","unstructured":"Deftereos SG, Siasos G, Giannopoulos G, et al.. The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): rationale and study design. Hellenic J Cardiol. 2020, 61:42-5. 10.1016\/j.hjc.2020.03.002","journal-title":"Hellenic J Cardiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13556","article-title":"Colchicine for the treatment of myocardial injury in patients with coronavirus disease 2019 (COVID-19)-an old drug with new life?","volume":"3","author":"Rabbani AB","year":"2020","unstructured":"Rabbani AB, Parikh RV, Rafique AM. Colchicine for the treatment of myocardial injury in patients with coronavirus disease 2019 (COVID-19)-an old drug with new life?. JAMA Netw Open. 2020, 3:e2013556. 10.1001\/jamanetworkopen.2020.13556","journal-title":"JAMA Netw Open"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.876718","article-title":"Colchicine for the treatment of cardiac injury in hospitalized patients with coronavirus disease-19","volume":"9","author":"Rabbani A","year":"2022","unstructured":"Rabbani A, Rafique A, Wang X, et al.. Colchicine for the treatment of cardiac injury in hospitalized patients with coronavirus disease-19. Front Cardiovasc Med. 2022, 9:876718. 10.3389\/fcvm.2022.876718","journal-title":"Front Cardiovasc Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck V","year":"2020","unstructured":"Kl\u00fcck V, Jansen TL, Janssen M, et al.. Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol. 2020, 2:e270-80. 10.1016\/s2665-9913(20)30065-5","journal-title":"Lancet Rheumatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26040976","article-title":"NLRP3 inflammasome inhibitors in cardiovascular diseases","volume":"26","author":"Mezzaroma E","year":"2021","unstructured":"Mezzaroma E, Abbate A, Toldo S. NLRP3 inflammasome inhibitors in cardiovascular diseases. Molecules. 2021, 26:10.3390\/molecules26040976","journal-title":"Molecules"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll RC","year":"2015","unstructured":"Coll RC, Robertson AA, Chae JJ, et al.. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015, 21:248-55. 10.1038\/nm.3806","journal-title":"Nat Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou E","year":"2021","unstructured":"Kyriazopoulou E, Poulakou G, Milionis H, et al.. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021, 27:1752-60. 10.1038\/s41591-021-01499-z","journal-title":"Nat Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Recovery Collaborative Group","year":"2021","unstructured":"Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021, 397:1637-45. 10.1016\/S0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically Ill patients with COVID-19","volume":"384","author":"Gordon AC","year":"2021","unstructured":"Gordon AC, Mouncey PR, Al-Beidh F, et al.. Interleukin-6 receptor antagonists in critically Ill patients with COVID-19. N Engl J Med. 2021, 384:1491-502. 10.1056\/NEJMoa2100433","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker PM","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al.. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195-207. 10.1056\/NEJMoa0807646","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393:31-39. 10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx N","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022, 146:1882-94. 10.1161\/CIRCULATIONAHA.122.059595","journal-title":"Circulation"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker PM","year":"2016","unstructured":"Ridker PM. From C-Reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016, 118:145-56. 10.1161\/CIRCRESAHA.115.306656","journal-title":"Circ Res"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.125.077665","article-title":"Low-dose colchicine attenuates clonal hematopoiesis in COLCOT","volume":"153","author":"Tardif JC","year":"2026","unstructured":"Tardif JC, Busque L, Geoffroy S, et al.. Low-dose colchicine attenuates clonal hematopoiesis in COLCOT. Circulation. 2026, 153:610-2. 10.1161\/CIRCULATIONAHA.125.077665","journal-title":"Circulation"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly SS","year":"2025","unstructured":"Jolly SS, d'Entremont MA, Lee SF, et al.. Colchicine in acute myocardial infarction. N Engl J Med. 2025, 392:633-42. 10.1056\/NEJMoa2405922","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/495657-a-unifying-model-of-inflammatory-amplification-insights-from-colchicine-across-cardiometabolic-and-infectious-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:05:03Z","timestamp":1781089503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/495657-a-unifying-model-of-inflammatory-amplification-insights-from-colchicine-across-cardiometabolic-and-infectious-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":52,"URL":"https:\/\/doi.org\/10.7759\/cureus.110588","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}